|
|
News Breaks
|
November 23, 2009
|
| 09:31 EDT |  | ONCY |
| theflyonthewall.com: | Oncolytics Biotech closes $12.75M unit offering | | Oncolytics Biotech Inc. announced that it has closed its previously announced $12.75M offering in which a syndicate of underwriters purchased 4.25M units of the Company, each unit comprised of one common share and 0.4 of a common share purchase warrant, at a price of $3.00 per unit. Each whole common share purchase warrant entitles the holder to acquire one common share of Oncolytics upon payment of $3.50 for a five year period commencing on the closing date of the offering, subject to an acceleration of the expiry date in certain circumstances. Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering. Canaccord Capital Corporation and Bloom Burton & Co. acted as Canadian co-managers for the offering. The Company has granted the underwriters an over-allotment option to purchase additional common shares and/or warrants in an amount up to 15%. Oncolytics intends to use the net proceeds from the offering to fund its previously announced Phase III combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers, its other clinical development and research and development activities, and for general corporate and working capital purposes. :theflyonthewall.com |
|
|
News For ONCY From The Last 14 Days Check below for free stories on ONCY the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
January 30, 2012
|
| 12:00 EDT |  | ONCY |
| theflyonthewall.com: | Oncolytics Biotech rises 28.5% | | Oncolytics Biotech is up 28.5%, or $1.01, to $4.56 :theflyonthewall.com |
| | 10:00 EDT | | ONCY |
| theflyonthewall.com: | Oncolytics Biotech rises 26.8% | | Oncolytics Biotech is up 26.8%, or 95c, to $4.50 :theflyonthewall.com |
|
|
|
|
|
